{
    "eid": "2-s2.0-85086511503",
    "title": "Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Ophthalmology",
            "@code": "2731",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anionic",
        "cationic",
        "Cyclosporine",
        "dry eye disease",
        "formulation"
    ],
    "authors": [
        "Louis Tong",
        "Chi Chin Sun",
        "Kyung Chul Yoon",
        "Ruben Lim Bon Siong",
        "Vilavun Puangsricharern",
        "Christophe Baudouin"
    ],
    "citedby-count": 1,
    "ref-count": 36,
    "ref-list": [
        "TFOS DEWS II definition and classification report",
        "New perspectives on dry eye definition and diagnosis: a consensus report by the asia dry eye society",
        "Dry eye: diagnosis and current treatment strategies",
        "TFOS DEWS II epidemiology report",
        "A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial",
        "Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study",
        "Minimal clinically important difference for the ocular surface disease index",
        "Modern approaches to the ocular delivery of cyclosporine A",
        "Relation between signs and symptoms of dry eye in the elderly. A population-based perspective",
        "Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review",
        "TFOS DEWS II report executive summary",
        "Diagnosing the severity of dry eye: a clear and practical algorithm",
        "TFOS DEWS II management and therapy report",
        "The pathophysiology of dry eye disease: what we know and future directions for research",
        "Keratitis in dry eye disease and topical ciclosporin A",
        "Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts",
        "Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb",
        "Evaluating the novel application of cyclosporine 0.1% in ocular surface disease",
        "Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits",
        "A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye",
        "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group",
        "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin a phase 2 study group",
        "Topical cyclosporine 0.05% for the prevention of dry eye disease progression",
        "Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal",
        "Evaluation of topical cyclosporine for the treatment of dry eye disease",
        "Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years",
        "Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial",
        "One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease",
        "Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program",
        "Persistence of efficacy of 0.1% cyclosporin a cationic emulsion in subjects with severe keratitis due to dry eye disease: a nonrandomized, open-label extension of the SANSIKA study",
        "The lack of association between signs and symptoms in patients with dry eye disease",
        "Reliability and validity of the ocular surface disease index",
        "TFOS DEWS II clinical trial design report",
        "A comparative review of Haute Autorite de Sante and National Institute for Health and Care Excellence health technology assessments of Ikervis(R) to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes"
    ],
    "affiliation": [
        {
            "affiliation-city": "Singapore City",
            "@id": "60095034",
            "affilname": "Duke-NUS Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60095034",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taoyuan",
            "@id": "60073391",
            "affilname": "Chang Gung University College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073391",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "@id": "60071449",
            "affilname": "University of the Philippines College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071449",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60031913",
            "affilname": "Chang Gung Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60024285",
            "affilname": "Singapore Eye Research Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024285",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Gwangju",
            "@id": "60017234",
            "affilname": "Chonnam National University Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017234",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60008970",
            "affilname": "Singapore National Eye Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008970",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60004689",
            "affilname": "Centre Hospitalier National d\u2018Ophtalmologie des Quinze-Vingts",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004689",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60001422",
            "affilname": "Sorbonne Universit\u00e9",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001422",
            "affiliation-country": "France"
        }
    ],
    "funding": [
        "Horus Pharma",
        "Santen Pharmaceutical Asia Pte. Ltd",
        "Santen"
    ]
}